BIT Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 136643 1 Year -0.02 -33.33
52 Week High 0.10
52 Week Low 0.03
BIT Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
ASX Australia Most Active Stocks
AGO 0.04 0.00%
AGO 0.04 0.00%
AGO 0.04 0.00%
SDL 0.01 0.00%
SDL 0.01 0.00%
SDL 0.01 0.00%
AYR 0.01 0.00%
AYR 0.01 0.00%
AYR 0.01 0.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
ADX 0.02 100.00%
ADX 0.02 100.00%
ADX 0.02 100.00%
DAU 0.03 50.00%
DAU 0.03 50.00%
BCN 0.03 50.00%
BCN 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
PNX 0.02 -33.33%
PNX 0.02 -33.33%
PNX 0.02 -33.33%
PNX 0.02 -33.33%
More..

Biotron Ltd (ASX: BIT)

BIT Technical Analysis 3
As on 23rd Feb 2017 BIT Share Price closed @ 0.04 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.06 & Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIT Target for February
1st Target up-side 0.04
2nd Target up-side 0.04
3rd Target up-side 0.04
1st Target down-side 0.04
2nd Target down-side 0.04
3rd Target down-side 0.04
BIT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotron.com.au
BIT Address
BIT
56 Delhi Road
Suite 19
North Ryde, NSW 2113
Australia
Phone: 61 2 9805 0488
Fax: 61 2 9805 0688
BIT Latest News
Technical Levels in Focus: Biotron Ltd (BIT.AX)   Benton Bulletin   - 21st Feb 17
Biotron's Success In HIV Trial: Is It Finally The Cure?   iTech Post   - 15th Feb 17
COMMENCEMENT OF BIT225 PHASE 2 HIV-1 CLINICAL TRIAL   PharmiWeb.com (press release)   - 13th Feb 17
Dengue Fever Therapeutics Pipeline Review, H1 2016 Edition - Research and Markets   Business Wire (press release)   - 13th Jul 16
Biotron Ltd shares rise after drug compounds show promise against Zika virus   Proactive Investors Australia   - 24th May 16
2016 Pipeline of Hepatitis C Market Covering 84 Companies   PR Newswire (press release)   - 19th May 16
Biotron Ltd has positive results from Phase 2 Hepatitis C drug study   Proactive Investors Australia   - 18th Mar 16
Biotron Phase 2 Hepatitis C Trial Success   PR Newswire (press release)   - 17th Mar 16
Biotron Limited cashes up as research refines Hepatitis C therapy   Proactive Investors Australia   - 06th Oct 15
Shares In Biotron Soar After A Successful Trial Of A Drug Against HIV And ...   Business Insider Australia   - 10th Oct 14
Interactive Technical Analysis Chart Biotron Ltd ( BIT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotron Ltd
BIT Business Profile
Biotron Limited develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1 in Australia. Its lead drug includes the BIT225, a viroporin inhibitor, which is in Phase 2 clinical trials used for the treatment of HCV and HIV infections. The company also has a portfolio of clinical and preclinical antiviral programs developing drugs targeting HCV, HIV, Dengue virus, and Influenza virus. Biotron Limited is based in North Ryde, Australia.